

News Coverage for Website

CCP News

Profit by Pakistan Today

Ijara capital, Noventa Pharma secure majority stake in Searle Pakistan

The Competition Commission of Pakistan (CCP) has granted approval for the acquisition of a 90.61 Percent shareholding in Searle Pakistan Limited (SPL) by Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL).

The CCP conducted a comprehensive competition assessment, identifying the relevant product market as 'pharmaceutical products', further segmented into therapeutic classes (e.g. cardiovascular drugs, antibiotics) and branded versus generic pharmaceuticals, said a press release issued here on Thursday.

The assessment determined that SPL's relatively low market share indicates the transaction would not create a dominant market position for the acquirers.

As the transaction is conglomerate in nature, no significant vertical integration concerns were identified.

The pharmaceutical sector in Pakistan operates within a regulated framework, characterized by moderate barriers to entry, including stringent regulatory approvals and substantial capital requirements.

The CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers.

SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products. ICPL, also a public unlisted company, is engaged in private equity and venture capital fund management services.

The approval underscores CCP's commitment to fostering competitive market dynamics while ensuring transactions align with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016.

[https://profit.pakistantoday.com.pk/2025/01/17/ijara-capital-noventa-pharma-secure-majority-stake-in-searle-pakistan/#:~:text=ISLAMABAD%3A%20The%20Competition%20Commission%20of,Private\)%20Limited%20\(NPL\).](https://profit.pakistantoday.com.pk/2025/01/17/ijara-capital-noventa-pharma-secure-majority-stake-in-searle-pakistan/#:~:text=ISLAMABAD%3A%20The%20Competition%20Commission%20of,Private)%20Limited%20(NPL).)

Pro Pakistani

Ijara Capital, Noventa Pharma Secure Majority Stake in Searle Pakistan

The Competition Commission of Pakistan (CCP) has granted approval for the acquisition of a 90.61 Percent shareholding in Searle Pakistan Limited (SPL) by Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL).

The CCP conducted a comprehensive competition assessment, identifying the relevant product market as 'pharmaceutical products', further segmented into therapeutic classes (e.g. cardiovascular drugs, antibiotics) and branded versus generic pharmaceuticals.

The assessment determined that SPL's relatively low market share indicates the transaction would not create a dominant market position for the acquirers. As the transaction is conglomerate in nature, no significant vertical integration concerns were identified.

The pharmaceutical sector in Pakistan operates within a regulated framework, characterized by moderate barriers to entry, including stringent regulatory approvals and substantial capital requirements. CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers.

SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products. ICPL, also a public unlisted company, is engaged in private equity and venture capital fund management services. NPL is a private limited company established as a Special Purpose Vehicle.

The approval underscores CCP's commitment to fostering competitive market dynamics while ensuring transactions align with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016.

<https://propakistani.pk/2025/01/16/ijara-capital-noventa-pharma-secure-majority-stake-in-searle-pakistan/>

Mettis Global

CCP approves ICPL, NPL's 90.61% stake acquisition in Searle Pakistan

The Competition Commission of Pakistan (CCP) has granted approval for Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL) to acquire a combined 90.61% stake in Searle Pakistan Limited (SPL).

This approval marks a significant development in the pharmaceutical sector, as per the press release issued today.

The CCP conducted a thorough competition assessment, defining the relevant product market as "pharmaceutical products."

This market was further categorized into therapeutic classes, such as cardiovascular drugs and antibiotics, as well as segmented into branded and generic pharmaceuticals.

The assessment concluded that SPL's relatively modest market share suggests the transaction would not result in a dominant market position for the acquirers.

Additionally, as the transaction is of a conglomerate nature, no substantial vertical integration concerns were identified.

The pharmaceutical sector in Pakistan functions within a regulated framework, marked by moderate entry barriers, including rigorous regulatory approvals and significant capital requirements.

CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers.

SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products.

ICPL, also a public unlisted company, is engaged in private equity and venture capital fund management services.

NPL is a private limited company established as a Special Purpose Vehicle.

The approval underscores CCP's commitment to fostering competitive market dynamics while ensuring transactions align with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016.

<https://mettisglobal.news/ccp-approves-icpl-npls-90-61-stake-acquisition-in-searle-pakistan/>

Bloom Pakistan

Ijara Capital and Noventa Pharma Secure Majority Stake in Searle Pakistan

The Competition Commission of Pakistan (CCP) has granted approval for the acquisition of a 90.61 Percent shareholding in Searle Pakistan Limited (SPL) by Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL).

The CCP conducted a comprehensive competition assessment, identifying the relevant product market as 'pharmaceutical products', further segmented into therapeutic classes (e.g. cardiovascular drugs, antibiotics) and branded versus generic pharmaceuticals.

The assessment determined that SPL's relatively low market share indicates the transaction would not create a dominant market position for the acquirers. As the transaction is conglomerate in nature, no significant vertical integration concerns were identified.

The pharmaceutical sector in Pakistan operates within a regulated framework, characterized by moderate barriers to entry, including stringent regulatory approvals and substantial capital requirements. CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers.

SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products. ICPL, also a public unlisted company, is engaged in private equity and venture capital fund management services. NPL is a private limited company established as a Special Purpose Vehicle.

The approval underscores CCP's commitment to fostering competitive market dynamics while ensuring transactions align with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016.

<https://www.bloompakistan.com/ijara-capital-and-noventa-pharma-secure-majority-stake-in-searle-pakistan/>

The AZB News

Ijara Capital and Noventa Pharma Secure Majority Stake in Searle Pakistan

The Competition Commission of Pakistan (CCP) has granted approval for the acquisition of a 90.61 Percent shareholding in Searle Pakistan Limited (SPL) by Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL).

The CCP conducted a comprehensive competition assessment, identifying the relevant product market as 'pharmaceutical products', further segmented into therapeutic classes (e.g. cardiovascular drugs, antibiotics) and branded versus generic pharmaceuticals. The assessment determined that SPL's relatively low market share indicates the transaction would not create a dominant market position for the acquirers. As the transaction is conglomerate in nature, no significant vertical integration concerns were identified.

The pharmaceutical sector in Pakistan operates within a regulated framework, characterized by moderate barriers to entry, including stringent regulatory approvals and substantial capital requirements. CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers.

SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products. ICPL, also a public unlisted company, is engaged in private equity and venture capital fund management services. NPL is a private limited company established as a Special Purpose Vehicle.

The approval underscores CCP's commitment to fostering competitive market dynamics while ensuring transactions align with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016.

<https://theazb.com/ijara-capital-and-noventa-pharma-secure-majority-stake-in-searle-pakistan/>

Associated Press of Pakistan

Ijara capital, Noventa Pharma secure majority stake in Searle Pakistan

The Competition Commission of Pakistan (CCP) has granted approval for the acquisition of a 90.61 Percent shareholding in Searle Pakistan Limited (SPL) by Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL).

The CCP conducted a comprehensive competition assessment, identifying the relevant product market as 'pharmaceutical products', further segmented into therapeutic classes (e.g. cardiovascular drugs, antibiotics) and branded versus generic pharmaceuticals, said a press release issued here on Thursday.

The assessment determined that SPL's relatively low market share indicates the transaction would not create a dominant market position for the acquirers.

As the transaction is conglomerate in nature, no significant vertical integration concerns were identified.

The pharmaceutical sector in Pakistan operates within a regulated framework, characterized by moderate barriers to entry, including stringent regulatory approvals and substantial capital requirements.

The CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers.

SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products. ICPL, also a public unlisted company, is engaged in private equity and venture capital fund management services.

NPL is a private limited company established as a Special Purpose Vehicle.

The approval underscores CCP's commitment to fostering competitive market dynamics while ensuring transactions align with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016.

<https://www.app.com.pk/business/ijara-capital-noventa-pharma-secure-majority-stake-in-searle-pakistan/>

Minute Mirror

Ijara capital, Noventa pharma take majority stake in Searle Pakistan

The Competition Commission of Pakistan acquiring a 90.61% stake in Searle Pakistan Limited (SPL).

The CCP carried out an in-depth competition review, categorizing the relevant market as 'pharmaceutical products,' further divided into therapeutic classes (such as cardiovascular drugs and antibiotics) and branded versus generic pharmaceuticals. The analysis concluded that SPL's modest market share means the acquisition would not result in a dominant market position for Ijara Capital and Noventa Pharma. Since the transaction is conglomerate based, no major concerns regarding vertical integration were raised.

Pakistan's pharmaceutical sector operates under a regulated environment with moderate entry barriers, including strict regulatory approvals and high capital requirements. The CCP's assessment found that the acquisition would not increase these barriers or harm consumers.

SPL is a public unlisted company that imports, manufactures, and sells pharmaceutical products. ICPL, also a public unlisted company, focuses on private equity and venture capital management, while NPL is a private limited company set up as a Special Purpose Vehicle.

The approval highlights the CCP's commitment to promoting competitive market dynamics and ensuring compliance with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016.

<https://minutemirror.com.pk/ijara-capital-noventa-pharma-take-majority-stake-in-searle-pakistan-340845/>

اجارا کیپیٹل اور نووینٹا فارما نے سیرل پاکستان کے اکثریتی حصص حاصل کر لئے

کمپنیشن کمیشن آف (سی سی پی) نے اجارا کیپیٹل پارٹنرز لمیٹڈ اور نووینٹا فارما (پرائیویٹ) لمیٹڈ کی جانب سے سیرل پاکستان لمیٹڈ میں 90.61 فیصد شیئر ہولڈنگ کے حصول کی منظوری دے دی ہے۔ سی سی پی نے اس ٹرانزیکشن میں 'دواسازی کی مصنوعات' کو متعلقہ مصنوعات کی مارکیٹ کے طور پر شناخت کیا ہے۔

سی سی پی فیز 1 جائزہ سے ظاہر ہوا کہ سیرل پاکستان متعلقہ مارکیٹ میں کم مارکیٹ شیئر رکھتی ہے اس لئے یہ ٹرانزیکشن حصول کنندگان کے لئے مارکیٹ میں بالادست پوزیشن حاصل کرنے کا باعث نہیں بنے گی۔ پاکستان میں فارماسیوٹیکل سیکٹر ایک ریگولیٹڈ فریم ورک کے اندر کام کرتا ہے، جس میں نئے داخلے ہونے والوں کیلئے ریگولیٹری منظوری اور بھاری سرمائے جیسی ضروریات کا سامنا پڑ سکتا ہے

سی سی پی جائزہ سے ظاہر ہوا کہ یہ ٹرانزیکشن ان رکاوٹوں میں اضافے اور صارفین پر منفی اثر ڈالنے کا باعث نہیں بنے گی۔ سیرل پاکستان لمیٹڈ پاکستان میں کام کرنے والی ایک پبلک آن لیسٹڈ کمپنی ہے جو فارماسیوٹیکل مصنوعات کی درآمد، تیاری اور فروخت میں مہارت رکھتی ہے۔ اجارا کیپیٹل پارٹنرز لمیٹڈ بھی ایک پبلک آن لیسٹڈ کمپنی ہے جو پرائیویٹ ایکویٹی اور وینچر کیپیٹل فنڈ مینجمنٹ سروسز کے کام میں مصروف ہے۔ جبکہ نووینٹا فارما ایک پرائیویٹ لمیٹڈ کمپنی ہے۔ یہ منظوری مارکیٹ میں کمپنیشن کے نئے امکانات کے فروغ کے لیے سی سی پی کے عزم کی نشاندہی کرتی ہے۔

<https://www.urdupoint.com/business/news-detail/live-news-4300852.html>



اجارا کیپیٹل اور نووینٹا فارما نے سیرل پاکستان کے اکثریتی حصص حاصل کر لئے

اسلام آباد کمپنیشن کمیشن آف (سی سی پی) نے اجارا کیپیٹل پارٹنرز لمیٹڈ اور نووینٹا فارما (پرائیویٹ) لمیٹڈ کی جانب سے سیرل پاکستان لمیٹڈ میں 90.61 فیصد شیئر ہولڈنگ کے حصول کی منظوری دے دی ہے۔ یہ منظوری مارکیٹ میں کمپنیشن کے نئے امکانات کے فروغ کے لیے سی سی پی کے عزم کی نشاندہی کرتی ہے۔

سی سی پی نے اس ٹرانزیکشن میں 'دواسازی کی مصنوعات' کو متعلقہ مصنوعات کی مارکیٹ کے طور پر شناخت کیا ہے۔ سی سی پی فیز 1 جائزہ سے ظاہر ہوا کہ سیرل پاکستان متعلقہ مارکیٹ میں کم مارکیٹ شیئر رکھتی ہے اس لئے یہ ٹرانزیکشن حصول کنندگان کے لئے مارکیٹ میں بالادست پوزیشن حاصل کرنے کا باعث نہیں بنے گی۔

پاکستان میں فارماسیوٹیکل سیکٹر ایک ریگولیٹڈ فریم ورک کے اندر کام کرتا ہے، جس میں نئے داخلے ہونے والوں کے لئے ریگولیٹری منظوری اور بھاری سرمائے جیسی ضروریات کا سامنا پڑ سکتا ہے۔ سی سی پی جائزہ سے ظاہر ہوا کہ یہ ٹرانزیکشن ان رکاوٹوں میں اضافے اور صارفین پر منفی اثر ڈالنے کا باعث نہیں بنے گی۔

سیرل پاکستان لمیٹڈ پاکستان میں کام کرنے والی ایک پبلک آن لیسٹڈ کمپنی ہے جو فارماسیوٹیکل مصنوعات کی درآمد، تیاری اور فروخت میں مہارت رکھتی ہے۔ اجارا کیپیٹل پارٹنرز لمیٹڈ بھی ایک پبلک آن لیسٹڈ کمپنی ہے جو پرائیویٹ ایکویٹی اور وینچر کیپیٹل فنڈ مینجمنٹ سروسز کے کام میں مصروف ہے۔ جبکہ نووینٹا فارما ایک پرائیویٹ لمیٹڈ کمپنی ہے۔

<https://urdu.bloompakistan.com/archives/25906>

Ijara capital, Noventa Pharma secure majority stake in Searle Pakistan

ISLAMABAD

STAFF REPORT

The Competition Commission of Pakistan (CCP) has granted approval for the acquisition of a 90.61 Percent shareholding in Searle Pakistan Limited (SPL) by Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL). The CCP conducted a comprehensive competition assessment, identifying the relevant product market as 'pharmaceutical products', further segmented into therapeutic classes (e.g. cardiovascular drugs, antibiotics) and branded versus generic pharmaceuticals, said a press release issued here on Thursday. The assessment determined that SPL's relatively low market share indicates the transaction would not create a dominant market position for the acquirers. As the transaction is conglomerate in nature, no significant vertical integration concerns were identified. The pharmaceutical sector in Pakistan operates within a regulated framework, characterized by moderate barriers to entry, including stringent regulatory approvals and substantial capital requirements. The CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers. SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products.

Ijara capital, Noventa Pharma secure majority stake in Searle Pakistan

The Competition Commission of Pakistan (CCP) has granted approval for the acquisition of a 90.61 Percent shareholding in Searle Pakistan Limited (SPL) by Ijara Capital Partners Limited (ICPL) and Noventa Pharma (Private) Limited (NPL).

The CCP conducted a comprehensive competition assessment, identifying the relevant product market as 'pharmaceutical products', further segmented into therapeutic classes (e.g. cardiovascular drugs, antibiotics) and branded versus generic pharmaceuticals, said a press release issued here on Thursday.

The assessment determined that SPL's relatively low market share indicates the transaction would not create a dominant market position for the acquirers. As the transaction is conglomerate in nature, no significant vertical integration concerns were identified.

The pharmaceutical sector in Pakistan operates within a regulated framework, characterized by moderate barriers to entry, including stringent regulatory approvals and substantial capital requirements. The CCP's evaluation concluded that the transaction is unlikely to heighten these barriers or adversely impact consumers.

SPL, a public unlisted company incorporated under the laws of Pakistan, specializes in the import, manufacture and sale of pharmaceutical products. ICPL, also a public unlisted company, is engaged in private equity and venture capital fund management services.

NPL is a private limited company established as a Special Purpose Vehicle.

The approval underscores CCP's commitment to fostering competitive market dynamics while ensuring transactions align with the Competition Act, 2010, and the Competition (Merger Control) Regulations 2016. APP

عوامي حقن جي ترجمان، ڪمپيوٽر تي پهرين مڪمل اخبار ABC

ڪراچي، حيدرآباد ۽ سکر مان هڪ ئي وقت شايع ٿيندڙ CERTIFIED

Daily AWAMI AWAZ

روزاني

عوامي آواز

روزاني عوامي آواز (6) جمعو 17 جنوري 2025 ع

اجارا ڪيپيٽل ۽ نوونٽا فارما، سيريل پاڪستان حصيداري حاصل ڪري ورتي

90 سيڪڙو حصيداريءَ جي ڪمپيٽيشن ڪميشن آف پاڪستان پاران منظوري ڏني وئي

اجاره ڪيپيٽل پارٽنر لميٽيڊ هڪ پرائيوٽ ڪمپني آهي، جنهن جي ساڪ تمام سٺي آهي

ٽرانزيڪشن جي نتيجي ۾ حاصل ڪندڙن لاءِ مارڪيٽ هڪ هٿيءَ واري حيثيت حاصل نه رهندي. سيريل پاڪستان لميٽيڊ هڪ عوامي غير فهرست ٿيل ڪمپني آهي جيڪا پاڪستان ۾ دواسازي جي شين جي درآمد، تيار ڪرڻ ۽ وڪري ۾ ماهر آهي. اجارا ڪيپيٽل پارٽنر لميٽيڊ پڻ هڪ عوامي غير فهرست ٿيل ڪمپني آهي جيڪا پرائيوٽ ايڪوٽي ۽ وينچر ڪيپيٽل فنڊ مئنيجمينٽ سروسز ۾ مصروف آهي. جڏهن ته نوونٽا فارما هڪ پرائيوٽ لميٽيڊ ڪمپني آهي.

اسلام آباد (پ ر) ڪمپيٽيشن ڪميشن آف پاڪستان (سي سي سي پي) اجارا ڪيپيٽل پارٽنر لميٽيڊ ۽ نوونٽا فارما (پرائيوٽ) لميٽيڊ پاران سيريل پاڪستان لميٽيڊ ۾ 90.61 سيڪڙو شيئر هولڊنگ جي حصول جي منظوري ڏئي ڇڏي آهي. سي سي سي پي هن ٽرانزيڪشن ۾ دوا ساز شين سان لاڳاپيل پراڊڪٽس ڪي مارڪيٽ ۾ سڃاڻپ ڏني وئي. سي سي سي پي فيز 1 جي جائزي مان ظاهر ٿيو ته سيريل پاڪستان جو لاڳاپيل مارڪيٽ مارڪيٽ شيئر گهٽ آهي تنهن ڪري هن